Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
复制标题
DOI:
10.1080/19420862.2021.2020082
复制
发表时间:
2022-01
期刊:
影响因子:
5.3
通讯作者:
Martin ACR
中科院分区:
文献类型:
--
作者:
Khetan R;Curtis R;Deane CM;Hadsund JT;Kar U;Krawczyk K;Kuroda D;Robinson SA;Sormanni P;Tsumoto K;Warwicker J;Martin ACR
Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly enabling the development of predictive models and computational tools for the “developability assessment” of antibody drug candidates. Here, we provide an overview of the antibody informatics tools applicable to the prediction of developability issues such as stability, aggregation, immunogenicity, and chemical degradation. We further evaluate the opportunities and challenges of using biopharmaceutical informatics for drug discovery and optimization. Finally, we discuss the potential of developability guidelines based on in silico metrics that can be used for the assessment of antibody stability and manufacturability.
登录
查看更多内容
影响因子:
8.7
作者:
Corrie BD;Marthandan N;Zimonja B;Jaglale J;Zhou Y;Barr E;Knoetze N;Breden FMW;Christley S;Scott JK;Cowell LG;Breden F
通讯作者:
Breden F
影响因子:
14.9
作者:
Cheng, J;Randall, AZ;Sweredoski, MJ;Baldi, P
通讯作者:
Baldi, P
影响因子:
7.3
作者:
Christley S;Scarborough W;Salinas E;Rounds WH;Toby IT;Fonner JM;Levin MK;Kim M;Mock SA;Jordan C;Ostmeyer J;Buntzman A;Rubelt F;Davila ML;Monson NL;Scheuermann RH;Cowell LG
通讯作者:
Cowell LG
影响因子:
14.9
作者:
Chailyan A;Tramontano A;Marcatili P
通讯作者:
Marcatili P
影响因子:
5.3
作者:
Bailly, Marc;Mieczkowski, Carl;Fayadat-Dilman, Laurence
通讯作者:
Fayadat-Dilman, Laurence